Tylenol Turmoil: Judges Weigh Stunning Comeback

A wooden gavel next to a stethoscope on a dark surface

Federal judges are weighing whether to bring back hundreds of Tylenol–autism lawsuits even as top medical experts still say the science does not show the drug causes autism.

Story Snapshot

More than 500 lawsuits claiming prenatal Tylenol use led to autism or ADHD may be revived by a federal appeals court.
The Trump White House and federal health officials have warned of a “possible” autism risk, clashing with long‑standing medical guidance that acetaminophen is safe in pregnancy.
A 2023 federal ruling threw out expert testimony, saying there is no accepted scientific proof that prenatal acetaminophen causes autism.
Recent large studies and global reviews report no clear link between Tylenol use in pregnancy and autism or ADHD, deepening public confusion.

Appeals court puts Tylenol–autism fight back in the spotlight

Federal judges on a U.S. appeals court are now hearing arguments on whether to revive more than 500 private lawsuits that claim using Tylenol during pregnancy led to autism or attention deficit hyperactivity disorder in children. These cases were part of a larger group of claims against Kenvue and other sellers of acetaminophen, the generic name for Tylenol. The appeals judges are not deciding scientific truth. They are deciding if earlier rulings went too far when they blocked the lawsuits from even reaching a jury.

Families bringing these suits say drug makers and big retailers hid or ignored evidence that prenatal acetaminophen raises the risk of autism and attention deficit hyperactivity disorder. Their lawyers point to earlier research and a 2021 expert “consensus statement” warning that routine Tylenol use in pregnancy might not be safe and could be linked to higher autism rates. They argue companies had a duty to warn pregnant women but instead kept marketing Tylenol as the safest choice, especially for mothers who were already anxious and looking for trusted brands.

Trump administration warnings collide with medical consensus

In September 2025, President Donald Trump announced that the Food and Drug Administration would alert doctors to a possible connection between Tylenol use during pregnancy and autism and attention deficit hyperactivity disorder, telling pregnant women to limit use. The White House and the Department of Health and Human Services later issued guidance saying acetaminophen taken in pregnancy “may be associated” with increased risk of these conditions. These moves pleased many worried parents but shocked medical groups that had spent years telling women acetaminophen was the safest over‑the‑counter pain option.

Health Secretary Robert F. Kennedy Jr. himself added to the mixed messages. He said the link between Tylenol and autism was “quite suggestive” but also admitted there was not enough evidence to prove the drug causes autism. The Food and Drug Administration echoed that view, saying several studies show a possible association, yet the overall science is not strong enough to show a causal relationship between prenatal acetaminophen use and autism or attention deficit hyperactivity disorder. For many Americans, this sounds like Washington saying “maybe” and “maybe not” at the same time, which feeds distrust of federal health advice.

Courts and researchers say causation claim is not proven

In December 2023, U.S. District Judge Denise Cote issued a 148‑page ruling that barred plaintiff experts from telling a jury that Tylenol can cause autism when used in pregnancy. She found that none of the five experts offered a robust scientific framework for causation, and that there was no generally accepted scientific conclusion tying in‑utero acetaminophen exposure to autism or attention deficit hyperactivity disorder. After that ruling, roughly 400 to 500 consolidated cases were dismissed, leaving families angry and feeling the system cared more about corporate comfort than their children’s struggles.

Since then, new research has mostly strengthened the skeptics’ side. An April 2024 study funded by the National Institutes of Health and published in the Journal of the American Medical Association followed large groups of mothers and children and found no link between acetaminophen use in pregnancy and autism, attention deficit hyperactivity disorder, or intellectual disability. A review in the British Medical Journal likewise reported no clear evidence that prenatal acetaminophen causes autism or attention deficit hyperactivity disorder. A broader Lancet review of dozens of high‑quality studies also concluded there was no increased risk of neurodevelopmental disorders in children whose mothers used acetaminophen.

Big Pharma, political power, and parents caught in the middle

Kenvue, the maker of Tylenol, has taken a hard line in public and in court, saying there is “no credible data” proving a link and that current science does not support a causal relationship between acetaminophen and autism. The company stresses that acetaminophen remains the safest pain reliever for pregnant women when used as directed, and warns that fear‑based changes in guidance could push mothers toward riskier drugs. With billions of dollars and major law firms on its side, Kenvue’s position carries weight, but it also reinforces the feeling among many Americans that giant health companies can always out‑muscle ordinary families.

Kenvue's Tylenol nightmare is BACK! An appeals court just revived hundreds of lawsuits linking prenatal Tylenol to autism/ADHD. Massive financial uncertainty ahead despite that 4.3% dividend.$KVUE #Kenvue #LegalBattle https://t.co/q9goCAYg93 pic.twitter.com/MFvPkqd2T2

— Kavout (@kavout) July 13, 2026

Texas Attorney General Ken Paxton has tried to flip that script, suing Johnson & Johnson and Kenvue and accusing them of hiding evidence that acetaminophen increased the risk of autism and other disorders in unborn children. His lawsuit claims the companies marketed Tylenol aggressively to pregnant women while knowing about potential dangers, a charge Kenvue strongly denies. The Tylenol fight now sits at the crossroads of long‑running anger on both the left and the right: distrust of pharmaceutical giants, suspicion of government experts, and fear that profit and politics matter more than the health of mothers and children.

Why this case taps deep nationwide frustration

Many conservative Americans see this as another example of health elites ignoring possible risks to protect a profitable drug, while liberal Americans worry that political appointees are twisting science to score points with voters. Both sides share a core worry: the system does not tell the full truth when powerful interests are involved. Past waves of lawsuits over pregnancy drugs, like anti‑nausea medicines and antidepressants, often began with scary headlines and ended with judges saying the science was too weak to prove harm.

The Tylenol‑autism appeals now force hard questions. Who should mothers trust when the White House, federal regulators, courts, and drug makers send mixed signals? How should we weigh early, suggestive studies against larger research that finds no link? And why does it take lawsuits and political fights to push honest reviews of common drugs used by millions of families? Those questions go beyond Tylenol. They speak to a deeper fear that America’s health and legal systems answer first to money and power, not to parents trying to protect their children.